Chimeric Therapeutics
Chimeric Therapeutics is a results-driven cancer cell therapy company with a diversified portfolio including first-in-class autologous CAR T cell therapies and allogeneic NK cell therapies. Focused on discovery, development, and commercialization of innovative solutions, it aims to bring transformative therapies to patients with cancer. The company is led by a team of cell therapy pioneers and experts, and currently has four clinical trials in progress.
Industries
Nr. of Employees
small (1-50)
Chimeric Therapeutics
Level 3/62 Lygon St, Carlton, VIC 3053
Products
Autologous CAR T therapy targeting CDH17
A third-generation autologous CAR T candidate targeting the CDH17 antigen, optimised with combined co-stimulatory domains and preclinical evidence of tumour eradication with limited normal tissue toxicity.
Peptide-targeted CAR T therapy for glioblastoma
An autologous CAR T approach using a short peptide targeting domain derived from a natural peptide to broaden and specify tumour recognition in glioblastoma.
Allogeneic NK cell therapy platform
An off-the-shelf NK cell therapy platform under clinical evaluation for haematological and solid tumour indications with early clinical validation.
Autologous CAR T therapy targeting CDH17
A third-generation autologous CAR T candidate targeting the CDH17 antigen, optimised with combined co-stimulatory domains and preclinical evidence of tumour eradication with limited normal tissue toxicity.
Peptide-targeted CAR T therapy for glioblastoma
An autologous CAR T approach using a short peptide targeting domain derived from a natural peptide to broaden and specify tumour recognition in glioblastoma.
Allogeneic NK cell therapy platform
An off-the-shelf NK cell therapy platform under clinical evaluation for haematological and solid tumour indications with early clinical validation.
Services
End-to-end management of Phase 1 / 1b trials including protocol implementation, site engagement and dose-escalation operations.
Antigen discovery, antibody development and in vitro/in vivo validation studies to support candidate selection.
Development and optimisation of autologous manufacturing workflows including leukapheresis handling, engineering and expansion processes for clinical product supply.
Regulatory planning and interactions with authorities to pursue expedited pathways and support clinical advancement.
Business development activities to enable rapid commercial translation and partner collaborations.
End-to-end management of Phase 1 / 1b trials including protocol implementation, site engagement and dose-escalation operations.
Antigen discovery, antibody development and in vitro/in vivo validation studies to support candidate selection.
Development and optimisation of autologous manufacturing workflows including leukapheresis handling, engineering and expansion processes for clinical product supply.
Regulatory planning and interactions with authorities to pursue expedited pathways and support clinical advancement.
Business development activities to enable rapid commercial translation and partner collaborations.
Expertise Areas
- Cell therapy development
- Autologous CAR T therapy
- Allogeneic NK cell therapy
- Early-phase clinical trial management
Key Technologies
- Autologous CAR T cell therapy
- Allogeneic NK cell therapy platform
- Chimeric antigen receptor engineering (multi-costimulatory domains)
- Peptide-based tumour-targeting domains
News & Updates
Chimeric Therapeutics received fast-track designation from the US Food and Drug Administration (FDA) for its lead candidate CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
The company's CHM CDH17 clinical trial has advanced to Dose Level 2, with no safety concerns or off-target effects observed at Dose Level 1.
Dr. Jennifer Eads discusses her neuroendocrine cancer research and the clinical trial evaluating a CAR-T Therapy directed at CDH17.
CEO Dr. Rebecca McQualter discusses the progress of the company's clinical trials, focusing on its leading asset, CHM CDH17.
Announcement of FDA fast-track designation for CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours.
CEO Dr. Rebecca McQualter discusses recent announcements and clinical trial updates.
Chimeric Therapeutics received fast-track designation from the US Food and Drug Administration (FDA) for its lead candidate CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
The company's CHM CDH17 clinical trial has advanced to Dose Level 2, with no safety concerns or off-target effects observed at Dose Level 1.
Dr. Jennifer Eads discusses her neuroendocrine cancer research and the clinical trial evaluating a CAR-T Therapy directed at CDH17.
CEO Dr. Rebecca McQualter discusses the progress of the company's clinical trials, focusing on its leading asset, CHM CDH17.
Announcement of FDA fast-track designation for CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours.
CEO Dr. Rebecca McQualter discusses recent announcements and clinical trial updates.